壮病患者死亡率的性别差异:韩国一项全国性队列研究
Jiwon Kim1,2, Namki Hong3, Jimi Choi4
1Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea, 10444.
European journal of endocrinology
|August 7, 2023
概括
与男性相比,患有壮症的女性面临的死亡率和并发症风险更高. 这项研究突出了巨大的性别差异,强调了需要量身定制的护理.
科学领域:
- 内分泌学 在内分泌学.
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 巨症是一种由生长激素过量引起的疾病,在死亡率和并发症方面报告了各种性别差异.
- 之前的研究表明,关于壮病患者的性别特异性结果的结果是相互矛盾的.
研究的目的:
- 为了评估性差异的死亡率和并发症的风险在患有壮病的患者中.
- 为了比较壮症患者和匹配的对照组之间的结果,分析性别特异性风险.
主要方法:
- 从2009年到2019年利用了韩国全国索赔数据库,其中包括1884名壮病患者和94,200名年龄和性别匹配的对照.
- 随访患者的中位数为5.51年,分析所有原因的死亡率和各种并发病的发病率.
主要成果:
- 宏壮病患者的全因死亡率 (HR 1.74) 比对照人群高,女性 (HR 2.17) 与男性 (HR 1.36) 的风险显著增加.
- 恶性瘤是导致死亡的主要原因. 年龄≥50岁的女性患有壮症的死亡率高于同龄男性. 在非手术治疗小组中,也观察到女性死亡风险较高.
- 患有壮症的患者患有主要不良心血管事件 (MACE),心房动,阻塞性睡眠呼吸暂停 (OSA),糖尿病 (DM),末期脏疾病 (ESRD),帕金森病 (PD),抑郁症和恶性病的风险增加. 妇女的OSA和DM风险较高.
结论:
- 与男性相比,女性的死亡率和壮症并发症的风险更高.
- 在调整了相关疾病,社会经济地位和生活方式因素后,死亡率的性别差异仍然存在.
更多相关视频
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
223
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
223
01:27Signs of Puberty
423
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
423
01:21Cancer Survival Analysis
384
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
384
01:29Bias in Epidemiological Studies
352
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
352
01:24Kaplan-Meier Approach
180
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
180